I'm very curious to see the next few presentations that Zenith will be putting out. If the rock stars in the second cohort are all still going it would now be 63 weeks. That's just two weeks away from 1.25 years from when dosing in that cohort started. The top three prescribed drugs for mCRPC have approximately $6 billion in annual sales. If Zenith can show that it is ZEN3694 that is causing patients to live that 1.25 years longer this could be an interesting year for us. This could be spectacular if the second radio graphic progression tests shows that the tumours are regressing as I don't know of any other drugs that show tumour regression.

I understand that there is a peer reviewed publication that has recently been submitted to a medical journal(don't know which one). Let's hope the journal it was submitted to doesn't sit on this too long.

tada